According to filings with the U.S. Securities and Exchange Commission, Ikena Oncology is raising $42,571,751.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Mark Manfredi played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ikena Oncology
Ikena Oncology, Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway. It also develops IK-595, designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175, a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors, including urothelial carcinomas. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

To learn more about Ikena Oncology, visit http://ikenaoncology.com/

Contact:
Mark Manfredi, Chief Executive Officer
857-273-8343
https://www.linkedin.com/in/mark-manfredi-50923a10/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.